Source: The Economic Times

Exelan Pharmaceuticals: Cipla seals Invagen and Exelan deals in US

The deal closure, that involved approvals from the US regulatory agencies, will see Cipla vault its sales from that market to around $400 million.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Est. Annual Revenue
$1.2M
Est. Employees
10
CEO Avatar

CEO

Update CEO

CEO Approval Rating

- -/100

Read more